Citations

Mayo Clinic

Clear

1111 citation(s) found for "Wu, Robin".

Fusobacterium-Positive and Streptococcal-Positive Pharyngitis
Uhl, James R., Gustafson, Daniel R., Rucinski, Stefanea L., Patel, Robin , Patel, Robin

Annals of Internal Medicine | June 15, 2015 | Volume: 162 | Issue: 12 | Pages: 876-877

10.7326/l15-5099-2 | PMID 26075767 Get It

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma
Attia, Steven , Okuno, Scott H. , Webber, Nicholas , Indelicato, Daniel J. , Jones, Robin L. , Sherman, Courtney E. , Kozak, Kevin R. , Cortese, Cherise , McFarland, Thomas, Trent, Jonathan C., Maki, Robert G. , Robinson, Steven I. , Sherman, Courtney, Cortese, Cherise M, Bagaria, Sanjay P. , Maki, Robert G , Jones, Robin L , Indelicato, Daniel J

Rare Tumors | June 15, 2015 | Volume: 7 | Issue: 2 | Pages: 86-88

10.4081/rt.2015.5992 | PMID 26266019 Get It

We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.
Evaluation of the FilmArray Blood Culture ID Panel on Biofilms Dislodged from Explanted Arthroplasties for Prosthetic Joint Infection Diagnosis
Vasoo, Shawn , Cunningham, Scott A. , Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jayawant N. , Hanssen, Arlen D. , Osmon, Douglas R. , Berbari, Elie F. , Patel, Robin , Abdel, Matthew P. , Patel, Robin , Cunningham, Scott A

Journal of Clinical Microbiology | May 28, 2015 | Volume: 53 | Issue: 8 | Pages: 2790-2792

10.1128/jcm.01333-15 | PMID 26019200 Get It

Standard Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Reagents May Inactivate Potentially Hazardous Bacteria
Cunningham, Scott A. , Patel, Robin , Patel, Robin , Cunningham, Scott A

Journal of Clinical Microbiology | May 28, 2015 | Volume: 53 | Issue: 8 | Pages: 2788-2789

10.1128/jcm.00957-15 | PMID 26019211 Get It

Antibiofilm Activity of Low-Amperage Continuous and Intermittent Direct Electrical Current
Schmidt-Malan, Suzannah M., Karau, Melissa J. , Cede, Julia , Greenwood‐Quaintance, Kerryl E. , Brinkman, Cassandra L., Mandrekar, Jayawant N. , Patel, Robin , Patel, Robin

Antimicrobial Agents and Chemotherapy | May 27, 2015 | Volume: 59 | Issue: 8 | Pages: 4610-4615

10.1128/aac.00483-15 | PMID 26014944 Get It

ABSTRACT Bacterial biofilms are difficult to treat using available antimicrobial agents, so new antibiofilm strategies are needed. We previously showed that 20, 200, and 2,000 μA of electrical current reduced bacterial biofilms of Staphylococcus aureus , Staphylococcus epidermidis , and Pseudomonas aeruginosa . Here, we tested continuous direct current at lower amperages, intermittent direct current, and combinations of surface materials (Teflon or titanium) and electrode compositions (stainless steel, graphite, titanium, or platinum) against S. aureus , S. epidermidis , and P. aeruginosa biofilms. In addition, we tested 200 or 2,000 μA for 1 and 4 days against biofilms of 33 strains representing 13 species of microorganisms. The logarithmic reduction factor was used to measure treatment effects. Using continuous current delivery, the lowest active amperage was 2 μA for 1, 4, or 7 days against P. aeruginosa and 5 μA for 7 days against S. epidermidis and S. aureus biofilms. Delivery of 200 μA for 4 h a day over 4 days reduced P. aeruginosa , S. aureus , and S. epidermidis biofilms on Teflon or titanium discs. A reduction of P. aeruginosa , S. aureus , and S. epidermidis biofilms was measured for 23 of 24 combinations of surface materials and electrode compositions tested. Four days of direct current delivery reduced biofilms of 25 of 33 strains studied. In conclusion, low-amperage current or 4 h a day of intermittent current delivered using a variety of electrode compositions reduced P. aeruginosa , S. aureus , and S. epidermidis biofilms on a variety of surface materials. The electricidal effect was observed against a majority of bacterial species studied.
Causes and Implications of the Disappearance of Rifampin Resistance in a Rat Model of Methicillin-Resistant Staphylococcus aureus Foreign Body Osteomyelitis
Brinkman, Cassandra L., Tyner, Harmony L. , Schmidt-Malan, Suzannah M., Mandrekar, Jayawant N. , Patel, Robin , Patel, Robin

Antimicrobial Agents and Chemotherapy | May 19, 2015 | Volume: 59 | Issue: 8 | Pages: 4481-4488

10.1128/aac.05078-14 | PMID 25987614 Get It

ABSTRACT Orthopedic foreign body-associated infections are often treated with rifampin-based combination antimicrobial therapy. We previously observed that rifampin-resistant and methicillin-resistant Staphylococcus aureus (MRSA) isolates were present 2 days after cessation of rifampin therapy in experimental foreign body osteomyelitis. Unexpectedly, only rifampin-susceptible isolates were detected 14 days after the completion of treatment. We studied two rifampin-resistant isolates recovered 2 days after treatment and one rifampin-susceptible isolate recovered 14 days after treatment. Growing these isolates alone in vitro or in vivo demonstrated no fitness defects; however, in mixed culture, rifampin-susceptible bacteria outcompeted rifampin-resistant bacteria. In vivo , two courses of rifampin treatment (25 mg/kg of body weight every 12 h for 21 days) yielded a greater decrease in bacterial quantity in the bones of treated animals 14 days following treatment than that in animals receiving a single course of treatment ( P = 0.0398). In infections established with equal numbers of rifampin-resistant and rifampin-susceptible bacteria, one course of rifampin treatment did not affect bacterial quantities. Rifampin-resistant and rifampin-susceptible isolates were recovered both 2 days and 14 days following treatment completion; however, the proportion of animals with rifampin-resistant isolates was lower at 14 days than that at 2 days following treatment completion ( P = 0.024). In untreated animals infected with equal numbers of rifampin-resistant and rifampin-susceptible bacteria for 4 weeks, rifampin-susceptible isolates were exclusively recovered, indicating the outcompetition of rifampin-resistant by rifampin-susceptible isolates. The data presented imply that although there is no apparent fitness defect in rifampin-resistant bacteria when grown alone, they are outcompeted by rifampin-susceptible bacteria when the two are present together. The findings also suggest that selected rifampin resistance may not persist in initially rifampin-susceptible infections following the discontinuation of rifampin.
Superantigens produced by catheter-associated Staphylococcus aureus elicit systemic inflammatory disease in the absence of bacteremia
Greenwood‐Quaintance, Kerryl E. , Karau, Melissa J. , Tilahun, Ashenafi Y. , Khaleghi, Shahryar, Chowdhary, Vaidehi , David, Chella S., Patel, Robin , Rajagopalan, Govindarajan , Chung, Jin-Won, Tilahun, Ashenafi, Khaleghi, Shahryar Rostamkolaei, Chowdhary, Vaidehi R, Chung, Jin-Won , Patel, Robin

Journal of Leukocyte Biology | May 16, 2015 | Volume: 98 | Issue: 2 | Pages: 271-281

10.1189/jlb.4a1214-577rr | PMID 25979434 Get It

Abstract SAgs, produced by Staphylococcus aureus, play a major role in the pathogenesis of invasive staphylococcal diseases by inducing potent activation of the immune system. However, the role of SAgs, produced by S. aureus, associated with indwelling devices or tissues, are not known. Given the prevalence of device-associated infection with toxigenic S. aureus in clinical settings and the potency of SAgs, we hypothesized that continuous exposure to SAgs produced by catheter-associated S. aureus could have systemic consequences. To investigate these effects, we established a murine in vivo catheter colonization model. One centimeter long intravenous catheters were colonized with a clinical S. aureus isolate producing SAgs or isogenic S. aureus strains, capable or incapable of producing SAg. Catheters were subcutaneously implanted in age-matched HLA-DR3, B6, and AEo mice lacking MHC class II molecules and euthanized 7 d later. There was no evidence of systemic infection. However, in HLA-DR3 transgenic mice, which respond robustly to SSAgs, the SSAg-producing, but not the nonproducing strains, caused a transient increase in serum cytokine levels and a protracted expansion of splenic CD4+ T cells expressing SSAg-reactive TCR Vβ8. Lungs, livers, and kidneys from these mice showed infiltration with CD4+ and CD11b+ cells. These findings were absent in B6 and AEo mice, which are known to respond poorly to SSAgs. Overall, our novel findings suggest that systemic immune activation elicited by SAgs, produced by S. aureus colonizing foreign bodies, could have clinical consequences in humans.
Metronidazole- and Carbapenem-Resistant Bacteroides thetaiotaomicron Isolated in Rochester, Minnesota, in 2014
Sadarangani, Sapna P. , Cunningham, Scott A. , Jeraldo, Patricio , Wilson, John , Khare, Reeti , Patel, Robin , Jeraldo, Patricio R , Sadarangani, Sapna , Patel, Robin , Cunningham, Scott A

Antimicrobial Agents and Chemotherapy | May 5, 2015 | Volume: 59 | Issue: 7 | Pages: 4157-4161

10.1128/aac.00677-15 | PMID 25941219 Get It

ABSTRACT Emerging antimicrobial resistance in members of the Bacteroides fragilis group is a concern in clinical medicine. Although metronidazole and carbapenem resistance have been reported in Bacteroides thetaiotaomicron , a member of the B. fragilis group, they have not, to the best of our knowledge, been reported together in the same B. thetaiotaomicron isolate. Herein, we report isolation of piperacillin-tazobactam-, metronidazole-, clindamycin-, ertapenem-, and meropenem-resistant B. thetaiotaomicron from a patient with postoperative intra-abdominal abscess and empyema. Whole-genome sequencing demonstrated the presence of nimD with at least a portion of IS 1169 upstream, a second putative nim gene, two β-lactamase genes (one of which has not been previously reported), two tetX genes, tetQ , ermF , two cat genes, and a number of efflux pumps. This report highlights emerging antimicrobial resistance in B. thetaiotaomicron and the importance of identification and antimicrobial susceptibility testing of selected anaerobic bacteria.
Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans
Bharat, Ankit , Cunningham, Scott A. , Kreisel, Daniel , DeWet, Charl J., Waites, Ken B. , Crabb, Donna M., Xiao, Li , Bhorade, Sangeeta , Ambalavanan, Namasivayam , Dilling, Daniel F. , Lowery, Erin M. , Astor, T., Krupnick, Alexander S. , DeCamp, Malcolm M., Patel, Robin , Budinger, G. R. Scott , Gelman, Andrew E , Hachem, Ramsey R. , Ison, Michael G. , Patel, Robin , Cunningham, Scott A

Science Translational Medicine | April 22, 2015 | Volume: 7 | Issue: 284 | Pages: No page available

10.1126/scitranslmed.aaa8419 | PMID 25904745 Get It

Disseminated infection with Ureaplasma species causes fatal hyperammonemia syndrome in lung transplant recipients, likely by disrupting ammonia metabolism.